
Artur Jurczyszyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2296997/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 297-304.	0.4	11
2	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. Leukemia and Lymphoma, 2022, 63, 984-990.	1.3	3
3	A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics, 2022, 30, 474-479.	2.8	5
4	Therapeutic role of eicosapentaenoic and arachidonic acid in benzo(a) pyrene-induced toxicity in HUVEC endothelial cells. Life Sciences, 2022, 293, 120345.	4.3	3
5	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2022, 107, 774-775.	3.5	2
6	The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment. Medicina (Lithuania), 2022, 58, 417.	2.0	3
7	Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 2022, 12, 45.	6.2	57
8	Monoclonal gammopathy of renal significance (MGRS): Realâ€world data on outcomes and prognostic factors. American Journal of Hematology, 2022, 97, 877-884.	4.1	12
9	Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. Molecules, 2022, 27, 79.	3.8	4
10	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica, 2021, 106, 601-604.	3.5	2
11	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica, 2021, 106, 1182-1187.	3.5	27
12	Common gene variants within 3′â€untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	5.1	3
13	Leukaemia cutis for clinicians, a literature review. Postepy Dermatologii I Alergologii, 2021, 38, 359-365.	0.9	8
14	Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death and Disease, 2021, 12, 206.	6.3	13
15	Amyloidosis, extramedullary plasmacytoma and light chain disease: impressive results of daratumumab therapy. Polish Archives of Internal Medicine, 2021, 131, 297-298.	0.4	3
16	Expert review on softâ€ŧissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	2.5	67
17	Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics, 2021, 10, 299.	3.7	23
18	Erythropoietin: a story of a discovery with Polish contribution. Polish Archives of Internal Medicine, 2021, 131, 317-319.	0.4	1

#	Article	IF	CITATIONS
19	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	5.1	3
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
21	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. Journal of Hematology and Oncology, 2021, 14, 54.	17.0	75
22	Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal, 2021, 11, 74.	6.2	10
23	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. Polish Archives of Internal Medicine, 2021, 131, 527-534.	0.4	4
24	MO128RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
25	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Molecular Cancer, 2021, 20, 84.	19.2	33
26	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers, 2021, 13, 4666.	3.7	10
27	Elements of Immunoglobulin E Network Associate with Aortic Valve Area in Patients with Acquired Aortic Stenosis. Biomedicines, 2021, 9, 23.	3.2	1
28	Non-secretory multiple myeloma: Diagnosis and management. Advances in Clinical and Experimental Medicine, 2021, 31, 95-100.	1.4	5
29	Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. Blood, 2021, 138, 2695-2695.	1.4	0
30	Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia. Blood, 2021, 138, 546-546.	1.4	1
31	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	1.4	6
32	Clinical implications of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematologica Polonica, 2021, 52, 18-28.	0.3	5
33	Current status and achievements of Polish haemato-oncology. Acta Haematologica Polonica, 2021, 52, 4-17.	0.3	6
34	Cereblon (<i>CRBN</i>) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia and Lymphoma, 2020, 61, 699-706.	1.3	3
35	Clostridium difficile caused changes in fatty acids profile and resolvin D1 content in plasma of infected patients. European Journal of Gastroenterology and Hepatology, 2020, 32, 318-324.	1.6	1
36	P0712TRANSGELIN AS A POTENTIAL MARKER OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

#	Article	IF	CITATIONS
37	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer, 2020, 126, 5077-5087.	4.1	47
38	Interaction between functional polymorphisms in FCER1A and TLR2 and the severity of atopic dermatitis. Human Immunology, 2020, 81, 709-713.	2.4	5
39	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	1.3	6
40	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	5.2	8
41	Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	4
42	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
43	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. Advances in Medical Sciences, 2020, 65, 429-436.	2.1	2
44	P0745URINE TIMP-2 AND IGFBP-7- NEW BIOMARKERS OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
45	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	13.7	188
46	Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway. BMC Complementary Medicine and Therapies, 2020, 20, 179.	2.7	11
47	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 767.	2.8	16
48	New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. Journal of Clinical Medicine, 2020, 9, 1652.	2.4	9
49	Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group. Archives of Medical Science, 2020, , .	0.9	1
50	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	4.1	11
51	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. Transplantation Proceedings, 2020, 52, 2186-2192.	0.6	3
52	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3
53	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. Clinical Hematology International, 2020, 2, 133.	1.7	5
54	Monoclonal gammopathies of undetermined significance and smoldering myeloma. Acta Haematologica Polonica, 2020, 51, 193-202.	0.3	0

#	Article	IF	CITATIONS
55	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. Polish Archives of Internal Medicine, 2020, 130, 106-111.	0.4	1
56	Professor Tadeusz Tempka (1885–1974). Polish Archives of Internal Medicine, 2020, 130, 924-925.	0.4	0
57	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	1.4	0
58	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	1.3	13
59	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	1.3	23
60	Hematogenous extramedullary relapse in multiple myeloma ―a multicenter retrospective study in 127 patients. American Journal of Hematology, 2019, 94, 1132-1140.	4.1	24
61	New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. Journal of Clinical Medicine, 2019, 8, 1828.	2.4	12
62	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
63	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. Nephrology Dialysis Transplantation, 2019, 34, 1440-1452.	0.7	10
64	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, 2019, 133, 1953-1963.	1.4	94
65	18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Wspolczesna Onkologia, 2019, 23, 23-31.	1.4	9
66	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia, 2019, 33, 2324-2330.	7.2	33
67	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis. Pharmacological Reports, 2019, 71, 473-477.	3.3	3
68	Fatty acids and selected endocannabinoids content in cerebrospinal fluids from patients with neuroinfections. Metabolic Brain Disease, 2019, 34, 331-339.	2.9	4
69	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	1.3	11
70	Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. Blood, 2019, 134, 782-782.	1.4	5
71	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood, 2019, 134, 1893-1893.	1.4	3
72	The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2019, 134, 1899-1899.	1.4	2

#	Article	IF	CITATIONS
73	Abnormal hemostasis screening tests leading to diagnosis of multiple myeloma. Acta Haematologica Polonica, 2019, 50, 32-35.	0.3	4
74	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 2019, 18, 5811-5820.	1.8	4
75	Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.3	0
76	Next-generation immunomodulatory drugs in multiple myeloma. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 791-802.	0.1	0
77	High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas. Current Problems in Cancer, 2018, 42, 268-275.	2.0	4
78	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	2.5	41
79	Stem cell mobilization in patients with dialysisâ€dependent multiple myeloma: Report of the Polish Myeloma Study Group. Journal of Clinical Apheresis, 2018, 33, 249-258.	1.3	3
80	The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2018, 19, 147032031881002.	1.7	6
81	Quiz What is your diagnosis?. Polish Journal of Pathology, 2018, 69, 107-107.	0.3	0
82	Intraoral manifestation ofÂsystemic AL amyloidosis with unique microscopic presentation ofÂintracellular amyloid deposition in striated muscles. Polish Journal of Pathology, 2018, 69, 200-204.	0.3	2
83	Autologous peripheral blood stem cell transplantation in dialysisâ€dependent multiple myeloma patients— <scp>DAUTOS</scp> Study of the Polish Myeloma Study Group. European Journal of Haematology, 2018, 101, 475-485.	2.2	11
84	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology, 2018, 183, 375-384.	2.5	11
85	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A caseâ€control study. American Journal of Hematology, 2018, 93, E238-E241.	4.1	6
86	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "realâ€world― study: Polish Myeloma Group experience. European Journal of Haematology, 2018, 101, 354-361.	2.2	13
87	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	1.4	3
88	Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo. Advances in Clinical and Experimental Medicine, 2018, 27, 153-158.	1.4	1
89	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.3	4
90	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600.	1.4	0

#	Article	IF	CITATIONS
91	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. Blood, 2018, 132, 2004-2004.	1.4	1
92	MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2018, 132, 1980-1980.	1.4	1
93	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	1.3	12
94	lgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
95	A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with antiâ€ <scp>J</scp> o‪ antibody. International Journal of Rheumatic Diseases, 2017, 20, 2171-2174.	1.9	8
96	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.3	5
97	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Annals of Hematology, 2017, 96, 1693-1698.	1.8	7
98	Nietypowe objawy kliniczne szpiczaka plazmocytowego. Acta Haematologica Polonica, 2017, 48, 189-194.	0.3	0
99	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	5.1	8
100	Whole-Body Low-Dose Computed Tomography (WBLDCT) in Assessment of Patients with Multiple Myeloma – Pilot Study and Standard Imaging Protocol Suggestion. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2017, 82, 356-363.	1.0	15
101	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis. Polish Archives of Internal Medicine, 2017, 127, 765-774.	0.4	7
102	Ultrafiltration rate and diabetes as useful indicators of cardiovascular-related death in hemodialysis patients below 60 years of age. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	0
103	Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World Journal of Gastroenterology, 2016, 22, 1067.	3.3	69
104	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
105	Characteristics and outcomes of patients with multiple myeloma aged 21–40Âyears versus 41–60Âyears: a multiâ€institutional caseâ€control study. British Journal of Haematology, 2016, 175, 884-891.	2.5	21
106	Resolvin D1 down-regulates CYP1A1 and PTGS2 gene in the HUVEC cells treated with benzo(a)pyrene. Pharmacological Reports, 2016, 68, 939-944.	3.3	7
107	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.3	10
108	Multiple Myeloma in Pregnancy—A Review of the Literature and a Case Series. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e39-e45.	0.4	12

#	Article	IF	CITATIONS
109	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 2016, 21, 333-342.	3.7	28
110	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	1.3	30
111	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	1.8	16
112	Monoklonalne przeciwciaÅ,a w szpiczaku plazmocytowym – przeÅ,om w terapii. Acta Haematologica Polonica, 2015, 46, 359-367.	0.3	1
113	The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment. Journal of Cancer, 2015, 6, 160-168.	2.5	12
114	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	1.6	330
115	ZajÄ™cie oÅ›rodkowego ukÅ,adu nerwowego w przebiegu szpiczaka plazmocytowego – opis przypadku i przeglÄd literatury. Acta Haematologica Polonica, 2015, 46, 242-247.	0.3	2
116	Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicology Letters, 2015, 236, 75-81.	0.8	14
117	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	12.8	38
118	n-3 Fatty acids as resolvents of inflammation in the A549 cells. Pharmacological Reports, 2015, 67, 610-615.	3.3	35
119	The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. European Journal of Haematology, 2015, 94, 109-114.	2.2	10
120	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	3.1	11
121	Plasma fatty acid profile in multiple myeloma patients. Leukemia Research, 2015, 39, 400-405.	0.8	35
122	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	5.1	30
123	Percutaneous Vertebroplasty for Pathological Vertebral Compression Fractures Secondary to Multiple Myeloma – Medium-Term and Long-Term Assessment of Pain Relief and Quality of Life. Advances in Clinical and Experimental Medicine, 2015, 24, 651-656.	1.4	11
124	Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor. Journal of Cancer, 2014, 5, 480-490.	2.5	15
125	HGF, sIL-6R and TGF-β ₁ Play a Significant Role in the Progression of Multiple Myeloma. Journal of Cancer, 2014, 5, 518-524.	2.5	17
126	Bortezomib for the treatment of multiple myeloma. Expert Review of Hematology, 2014, 7, 173-185.	2.2	17

#	Article	IF	CITATIONS
127	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group. Leukemia Research, 2014, 38, 788-794.	0.8	4
128	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 670-674.	2.5	13
129	Erythrocyte membrane fatty acids in multiple myeloma patients. Leukemia Research, 2014, 38, 1260-1265.	0.8	33
130	Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocytowego z uwzględnieniem efektów terapii z zastosowaniem bortezomibu. Acta Haematologica Polonica, 2014, 45, 26-34.	0.3	0
131	Rheological properties of erythrocytes in patients infected with Clostridium difficile. Postepy Higieny I Medycyny Doswiadczalnej, 2014, 68, 1397-1405.	0.1	4
132	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological Oncology, 2013, 31, 41-48.	1.7	39
133	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	1.6	307
134	ChÅ,oniak Hodgkina u osób w wieku podeszÅ,ym. Acta Haematologica Polonica, 2013, 44, 156-160.	0.3	0
135	Transient cortical blindness after coronary artery angiography. Postepy W Kardiologii Interwencyjnej, 2013, 1, 105-108.	0.2	5
136	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄce rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.3	5
137	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	7.2	664
138	Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles Blood, 2007, 110, 3515-3515.	1.4	0
139	Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs Blood, 2006, 108, 5027-5027.	1.4	0
140	C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma Blood, 2005, 106, 3395-3395.	1.4	0
141	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	2